Fibromuscular Dysplasia
Fibromuscular dysplasia is an atypical angiopathy that affects young to middle-aged and mainly female populations. It is a disease involving a mixed bag of histologic alterations that result in a narrowing of the arteries. By unleashing the power of rare cardiovascular disease therapy, Protheragen represents a drug discovery and development technology and service provider can offer a one-stop platform for fibromuscular dysplasia therapy research.
Introduction to Fibromuscular Dysplasia
Fibromuscular dysplasia is a rare systemic vascular condition, occurring in young females and representing 10-20% of cases of renal artery stenosis. Fibromuscular dysplasia is an idiopathic, non-inflammatory, non-atherosclerotic disease, most commonly affecting the renal and carotid arteries, but it may involve any arterial bed. Classically, stroke itself usually occurs among young adults, whereas fibromuscular dysplasia usually appears as renovascular hypertension. The coronary, aorta, and pulmonary arteries may also be involved in fibromuscular dysplasia.
Fig.1 Types of disease in fibromuscular dysplasia. (Petropoulos, T., et al., 2024)Pathogenesis of Fibromuscular Dysplasia
The exact etiology of fibromuscular dysplasia remains unclear but probably represents a multifactorial process that includes genetic, environmental, anatomic, and hormonal factors. It has been presumed that genetic factors are involved in the pathogenesis of fibromuscular dysplasia. Of most excitement also on the genetic front is the recent publication of findings of the first susceptibility locus for fibromuscular dysplasia, within the PHACTR1 gene, and replication of the association with fibromuscular dysplasia of the rs9349379 variant in five independent case-control cohorts.
Fig.2 Arterial involvement with fibromuscular dysplasia. (Narula, N., et al., 2018)Therapeutics Development for Fibromuscular Dysplasia
Antiplatelet Agents
Low-dose aspirin is frequently recommended to reduce thrombosis of the involved arteries. Aspirin prevents clots including platelet aggregation which is the underlying cause of strokes and other vascular events.
Antihypertensive Agents
Controlling hypertension is vital in fibromuscular dysplasia individuals; elevated blood pressure exacerbates arterial damage and increases complication risks. ACE inhibitors or angiotensin receptor blockers are the preferred drugs.
Our Services
Focused on indications such as fibromuscular dysplasia we provide a one-stop solution from diagnostics, through therapeutics, all the way to disease models. What sets Protheragen apart is that we implement complete services and work to cut cycle time from concept to cure so that the most revolutionary therapies get to those who most need them. With our services, our clients have a partner who has the knowledge and ability for complex drug development.
Therapeutic Development Services
Animal Model Development for Fibromuscular Dysplasia
The establishment of reliable animal models of fibromuscular dysplasia is important for furthering drug discovery and investigation of this rare cardiovascular disease. In response to this great demand, our company provides tailored animal model generation services for fibromuscular dysplasia. Using our broad experience in cardiovascular disease research, we generate customized models that accurately replicate the human phenotype of the disease.
Genetically Engineered Animal Models
Use of animal models with specific genetic modifications to mimic fibromuscular dysplasia-like vascular lesions.
- PHACTR1 knockdown model
- Other models
- UBR4 knockout model
Dedicated to ultimate quality, and it shows in Protheragen's overall offerings of service. Such rigorously designed preclinical services, pharmacokinetic studies, and safety evaluations should be made in compliance with the most stringent industry standards. This integrated development and research has the benefit of more efficient drug development as well as the reliability and efficacy of the therapeutics. Contact us today to see how we can help your project.
References
- Narula, Nupoor et al. "Fibromuscular Dysplasia: Contemporary Concepts and Future Directions." Progress in cardiovascular diseases 60.6 (2018): 580-585.
- Petropoulos, Taylor et al. "Fibromuscular Dysplasia: A Focused Review for the Cardiologist." CJC open 6.11 (2024): 1274-1288.
For research use only, not for clinical use.